# Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial

> **NCT06136585** · PHASE3 · RECRUITING · sponsor: **The Cleveland Clinic** · enrollment: 80 (estimated)

## Conditions studied

- Neuromuscular Blocks

## Interventions

- **DRUG:** 2 mg/kg sugammadex
- **DRUG:** 0.07 mg/kg neostigmine

## Key facts

- **NCT ID:** NCT06136585
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06136585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06136585, "Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial". Retrieved via AI Analytics 2026-09-13 from https://api.ai-analytics.org/clinical/NCT06136585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*